GlassScriptPhysician profile
Mark A Buczewski
NPI 1831136092
$1,977.19
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $639.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $396.39 | 2019-2020 | |
| Pfizer INC. | $181.65 | 2019-2020 | |
| Glaxosmithkline, LLC. | $177.35 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.69 | 2019-2020 | |
| Amarin Pharma, INC. | $158.60 | 2019-2020 | |
| Amgen INC. | $158.14 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $150.80 | 2019-2020 | |
| Novo Nordisk INC | $148.39 | 2019-2020 | |
| Lilly USA, LLC | $86.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $55.02 | 2019-2020 | |
| Abbvie INC. | $47.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $40.61 | 2019-2020 | |
| Sanofi Pasteur INC. | $33.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.28 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $25.85 | 2019-2020 | |
| Allergan, INC. | $23.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.52 | 2019 | |
| Astellas Pharma US INC | $18.78 | 2019 | |
| Indivior INC. | $15.02 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $9.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Buczewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.